Medicare Enrolled
Dr. Martha Lozano, MD
Pulmonary Disease · Chula Vista, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Lozano from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lozano?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Lozano
Dr. Martha Lozano is a pulmonary disease specialist in Chula Vista, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Lozano performed 4,429 Medicare services across 1,764 unique beneficiaries.
Between the years covered by Open Payments, Dr. Lozano received a total of $16,998 from 56 pharmaceutical and/or device companies across 885 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Lozano is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 6% volume in CA
$16,998 industry payments
Medicare Practice Summary
Medicare Utilization ↗4,429
Medicare services
Top 6% in CA for pulmonary disease
1,764
Unique beneficiaries
$64
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~221 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
1,857 | $64 | $94 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,317 | $64 | $130 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
362 | $103 | $185 |
| Hospital discharge day management, 30 minutes or less This service covers the final day of hospital care when the patient is being discharged. It includes coordination of care and instructions for the patient within a time frame of 30 minutes or less. |
344 | $65 | $120 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
107 | $12 | $30 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
92 | $1 | $10 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
76 | $79 | $140 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
75 | $95 | $151 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
45 | $18 | $32 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
39 | $33 | $80 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
39 | $47 | $90 |
| Lung volume test using gas dilution or washout A test that measures the amount of air in your lungs by using a gas dilution or washout method. |
38 | $35 | $80 |
| Methylprednisolone injection, up to 40 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, administered in a dose of up to 40 mg. |
26 | $3 | $15 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
12 | $143 | $270 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$16,998
Total received (2018-2024)
Avg $2,428/year across 7 years
Top 10% in CA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
56
Companies
885
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,998 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,364
2023
$2,553
2022
$2,413
2021
$2,539
2020
$2,230
2019
$2,578
2018
$2,320
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$605
AstraZeneca Pharmaceuticals LP
$438
Boehringer Ingelheim Pharmaceuticals, Inc.
$191
Grifols USA, LLC
$155
Regeneron Healthcare Solutions, Inc.
$153
Boston Scientific Corporation
$120
United Therapeutics Corporation
$106
Novo Nordisk Inc
$76
Mylan Specialty L.P.
$76
GENZYME CORPORATION
$64
Actelion Pharmaceuticals US, Inc.
$62
Insmed, Inc.
$60
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$44
Avadel CNS Pharmaceuticals, LLC
$43
Amgen Inc.
$28
ABBVIE INC.
$27
Genentech USA, Inc.
$25
Merck Sharp & Dohme LLC
$24
Abbott Laboratories
$23
Otsuka America Pharmaceutical, Inc.
$22
Takeda Pharmaceuticals U.S.A., Inc.
$21
Top 3 companies account for 52.2% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$3,541
GlaxoSmithKline, LLC.
$3,162
Boehringer Ingelheim Pharmaceuticals, Inc.
$2,194
Grifols USA, LLC
$1,063
Philips Electronics North America Corporation
$616
Actelion Pharmaceuticals US, Inc.
$590
Mylan Specialty L.P.
$401
Genentech USA, Inc.
$375
Sunovion Pharmaceuticals Inc.
$364
Novo Nordisk Inc
$352
Lilly USA, LLC
$270
Takeda Pharmaceuticals U.S.A., Inc.
$266
Janssen Pharmaceuticals, Inc
$262
Insmed, Inc.
$259
PFIZER INC.
$231
GENZYME CORPORATION
$226
Regeneron Healthcare Solutions, Inc.
$225
Merck Sharp & Dohme LLC
$223
Merck Sharp & Dohme Corporation
$218
United Therapeutics Corporation
$212
SANOFI-AVENTIS U.S. LLC
$186
Boston Scientific Corporation
$160
Radius Health, Inc.
$131
Advanced Respiratory, Inc
$119
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$116
Baxter Healthcare
$108
Novartis Pharmaceuticals Corporation
$106
Gilead Sciences, Inc.
$92
ABBVIE INC.
$76
Amgen Inc.
$75
E.R. Squibb & Sons, L.L.C.
$69
AbbVie Inc.
$56
Paratek Pharmaceuticals, Inc.
$48
Bayer HealthCare Pharmaceuticals Inc.
$44
Avadel CNS Pharmaceuticals, LLC
$43
Medtronic, Inc.
$42
Phadia US Inc.
$38
Abbott Laboratories
$37
La Jolla Pharmaceutical Company
$34
Esperion Therapeutics, Inc.
$32
Bayer Healthcare Pharmaceuticals Inc.
$32
Daiichi Sankyo Inc.
$32
Mallinckrodt Hospital Products Inc.
$28
Axsome Therapeutics, Inc.
$27
Shire North American Group Inc
$26
Medtronic Vascular, Inc.
$26
AbbVie, Inc.
$24
Otsuka America Pharmaceutical, Inc.
$22
Inogen, Inc.
$18
Tactile Systems Technology Inc
$17
Teva Pharmaceuticals USA, Inc.
$15
Seqirus USA Inc
$15
Azurity Pharmaceuticals, Inc.
$15
Electromed, Inc.
$14
Allergan, Inc.
$13
SANOFI PASTEUR INC.
$12
Top 3 companies account for 52.3% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · (9061) SRC Sol Space · ACTHAR · ADACEL · AIRSUPRA · ANORO · ANORO ELLIPTA · AirDuo Digihaler · Amitiza · Arikayce · Azure · BASAGLAR · BELSOMRA · BEVESPI AEROSPHERE · BREO · BREO ELLIPTA · BREZTRI · BREZTRI AEROSPHERE · BROVANA · CHANTIX · CUTAQUIG · Cathflo Activase · DIFICID · DUPIXENT · Dymista · ELIQUIS · EMGALITY · ENTRESTO · Esbriet · FARXIGA · FASENRA · Flexitouch Plus · Fluad Quadrivalent · GIAPREZA · GLASSIA · Hillrom - Life 2000 Ventilation System · Horizant · INJECTAFER · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · INVOKANA · ImmunoCAP · JANUVIA · JARDIANCE · Kerendia · LANTUS · LINZESS · LONHALA MAGNAIR · LUMRYZ · Life 2000 Ventilation System · MICRA · MOUNJARO · Mitra Clip system · NEXLETOL · NUCALA · NUZYRA · Non-Covered Product · OFEV · OPSUMIT · OPSUMIT MACITENTAN · Otezla · Ozempic · PRADAXA · PRALUENT · Prolastin-C · Prolastin-C Liquid · REXULTI · RYBELSUS · Repatha · Respiratoriy Care Undiv · SHINGRIX · SMARTVEST · SOLIQUA 100/33 · SPIRIVA RESPIMAT · STEGLATRO · STIOLTO RESPIMAT · SYMBICORT · Sunosi · TEZSPIRE · TOUJEO · TRADJENTA · TRELEGY ELLIPTA · TRULICITY · TYVASO · Tresiba · Trilogy 100 · Tymlos · UBRELVY · UPTRAVI · Utibron · VERQUVO · VRAYLAR · VersaCross Access Solution · Victoza · Volara System · WATCHMAN · WATCHMAN FLX · Wellcentive Undiv · XARELTO · XIFAXAN · XOLAIR · Xofluza · Xolair · YUPELRI · Yupelri · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 10% for pulmonary disease in CA.
Geographic Context
Pulmonary diseases within 10 mi
108
Per 100K population
3.3
County median income
$102,285
Nearest hospital
SHARP CHULA VISTA MEDICAL CENTER
6.9 mi
6.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Lozano is a clinical cardiology specialist, with above-average Medicare volume (top 6% in CA), with low-engagement industry engagement in the top 10% of CA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Lozano experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Lozano performed 1,857 hospital follow-up visit, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lozano receive payments from pharmaceutical companies?
Yes. Dr. Lozano received a total of $16,998 from 56 companies across 885 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lozano's costs compare to other pulmonary diseases in Chula Vista?
Dr. Lozano's average Medicare payment per service is $64. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lozano) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Chula Vista
Browse pulmonary diseases in Chula Vista ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in CA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in CA
Which CA pulmonary diseases receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology